“In the alliance management field, I hold Steve in high esteem based on our continuous business relationship from 2009 to present day. Steve is a visionary alliance leader and is outstanding in the planning and execution of highly complex projects. Steve’s experience at Lilly and AstraZeneca across the spectrum of deal types (complex co-development/commercialization alliances, asset acquisitions, and divestitures) is unparalleled in the industry. I consider him one of the best in the business.”
Harm-Jan Borgeld, Global Head Pharma Partnering, Roche
“Steve’s team together with a true cross-functional project set up at AstraZeneca delivered industry-leading transition support through our acquisition of established product brands, including Nexium™, Vimovo™ and Zomig™ as well as Crestor™.”
Helge Engel, Grunenthal
“Steve was a pleasure to work with as my alliance management counterpart, throughout the pandemic, during our COVID-19 vaccine (Vaxzevria) collaboration.Given the pace and intensity of our project, we found ourselves in problem-solving mode regularly.Through constant communication and creativity, we were always able to find a productive path forward.”
Maxine Allen, Director of Business Partnerships, University of Oxford
“Working with Steve is, without exaggeration, one of my most enjoyable and meaningful experiences during my professional career. I do not know any other person who knows Pharma-Bio business in Japan with more in-depth cultural understanding and affection than Steve. He is one of the best-known Western alliance professionals in the Pharma-Bio business community in Japan.”
Ichiro Okino, Head of Corporate Development, Teva Takeda Yakuhin